Rankings / Metabolic Health

Rosuvastatin / atorvastatin (statins)

Metabolic Health · HMG-CoA reductase inhibitor

Tier S

Reviewed by Read Off Label · Last reviewed · How we grade

statinanti-inflammatoryprescription
8.8 / 10
Tier S
Ev 10 Bn 10 Sf 7

Bottom line

Read Off Label grades Rosuvastatin / atorvastatin (statins) as S (8.8/10) based on very strong evidence, very strong benefit magnitude, and a low-med-risk safety profile.

SAMSON 2020 definitively demonstrated that most 'statin myalgia' is nocebo (same symptoms on placebo).

Studied, labeled, or reported-use context: Rosuvastatin 5-40 mg/day; atorvastatin 10-80 mg/day PO — Rx; not individualized guidance.

What the evidence says

SAMSON 2020 definitively demonstrated that most 'statin myalgia' is nocebo (same symptoms on placebo). Rosuvastatin gives the most LDL reduction per mg and has the longest half-life. High-intensity dosing (rosuvastatin 20-40 or atorvastatin 40-80) is the secondary prevention standard. Biohacker hostility to statins vastly outstrips evidence.

Mechanism

Competitive inhibition of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis; upregulates hepatic LDL receptors → reduced circulating LDL-C; also anti-inflammatory (CRP reduction), plaque stabilization, endothelial effects

Studied, labeled, or reported dose & route

Rosuvastatin 5-40 mg/day; atorvastatin 10-80 mg/day PO

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Rosuvastatin / atorvastatin (statins)'s effects?
Read Off Label rates the evidence for Rosuvastatin / atorvastatin (statins) as Very Strong and the benefit magnitude as very strong, producing an overall grade of S (8.8/10). SAMSON 2020 definitively demonstrated that most 'statin myalgia' is nocebo (same symptoms on placebo).
What safety findings are reported for Rosuvastatin / atorvastatin (statins)?
Rosuvastatin / atorvastatin (statins) has a low-med risk profile in the database. Low-Med (myalgias — mostly nocebo per SAMSON/SAMSON2 trials; rare rhabdomyolysis; small diabetes risk; minor LFT elevations; rare cognitive complaints) Legal status: Rx.
What doses or routes are reported for Rosuvastatin / atorvastatin (statins)?
Rosuvastatin 5-40 mg/day; atorvastatin 10-80 mg/day PO This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Rosuvastatin / atorvastatin (statins) work?
Competitive inhibition of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis; upregulates hepatic LDL receptors → reduced circulating LDL-C; also anti-inflammatory (CRP reduction), plaque stabilization, endothelial effects

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.